Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 5;13(1):e0190780.
doi: 10.1371/journal.pone.0190780. eCollection 2018.

EDI OCT evaluation of choroidal thickness in Stargardt disease

Affiliations

EDI OCT evaluation of choroidal thickness in Stargardt disease

Andrea Sodi et al. PLoS One. .

Abstract

Purpose: Choroidal thickness (CT) evaluation with EDI-OCT in Stargardt Disease (STGD), considering its possible association with some clinical features of the disease.

Methods: CT was evaluated in 41 STGD patients and in 70 controls. Measurements were performed in the subfoveal position and at 1000 μm nasally and temporally. CT average values in STGD and in the control group were first compared by means of Student's T test. Then, the possible association between CT and some clinical features was evaluated by means of linear regression analysis. Considered clinical parameters were: age, age on onset, duration of the disease, visual acuity, foveal thickness, Fishman clinical phenotype, visual field loss and ERG response.

Results: Average CT was not significantly different between controls and STGD patients. In the STGD group the correlation between CT and age (r = 0.22, p = 0.033) and age of onset (r = 0.05, p = 0.424) was modest, while that of CT with disease duration (r = 0.30, p<0.001) was moderate. CT and foveal thickness were also significantly but modestly correlated (r = 0.15, p = 0.033).

Conclusion: In our series average CT is not significantly changed in STGD in comparison with the controls. Nevertheless a choroidal thinning may be identified in the more advanced stages of the disease.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. The pictures compare an EDI-OCT scan where choroidal borders could be reliably identified (A) with another scan with ill-defined choroidal borders (B).
Fig 2
Fig 2. The graphs show the CT values across different subgroups of age (A), disease duration (B), visual acuity (C), as well as with Fishman phenotype (D), visual field severity stage (E) and ERG alteration grade (F).
Fig 3
Fig 3. The pictures outline the variability of choroidal thickness in STGD.
A) In this patient a thin choroid was associated with a Fishman phenotype 2, a relatively early onset (15 years) and a longer duration (11 years) of the disease. Visual acuity was 20/400, visual field loss consisted of paracentral scotomas and ERG photopic response was severely abnormal. B) In this patient a thick choroid was associated with a Fishman phenotype 1, a relatively late onset (25 years) and short duration (5 years) of the disease. Visual acuity was 20/200, visual field loss was limited to a central scotoma while ERG shows abnormal photopic response.

Similar articles

Cited by

References

    1. Blacharski PA. Fundus flavimaculatus In: Newsome DA ed. Retinal Dystrophies and Degenerations. Clinic New York: Raven Press; 1988:135–159.
    1. Yatsenko AN, Shroyer NF, Lewis RA, Lupski JR. Late-onset Stargardt disease is associated with missense mutations that map outside known functional regions of ABCR (ABCA4). Hum Genet. 2001. April;108(4):346–55. - PubMed
    1. Westeneng-van Haaften SC, Boon CJ, Cremers FP, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt’s disease. Ophthalmology. 2012. June;119(6):1199–210. doi: 10.1016/j.ophtha.2012.01.005 - DOI - PubMed
    1. Testa F, Rossi S, Sodi A, Passerini I, Di Iorio V, Della Corte M, et al. Correlation between photoreceptor layer integrity and visual function in patients with Stargardt disease: implications for gene therapy. Invest Ophthalmol Vis Sci. 2012. July 3; 53(8):4409–15. doi: 10.1167/iovs.11-8201 - DOI - PMC - PubMed
    1. Strauss RW, Muñoz B, Wolfson Y, Sophie R, Fletcher E, Bittencourt MG, et al. Assessment of estimated retinal atrophy progression in Stargardt macular dystrophy using spectral-domain optical coherence tomography. Br J Ophthalmol. 2015. November 14. - PMC - PubMed

Substances